Cargando…
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
BACKGROUND: Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the majority, the condition will irremediably relapse after 13 to 18 months. In this study, we hypothesized that patients’ outcome could be correlated to their immune cell p...
Autores principales: | Willems, Mégane, Scherpereel, Arnaud, Wasielewski, Eric, Raskin, Jo, Brossel, Hélène, Fontaine, Alexis, Grégoire, Mélanie, Halkin, Louise, Jamakhani, Majeed, Heinen, Vincent, Louis, Renaud, Duysinx, Bernard, Hamaidia, Malik, Willems, Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070849/ https://www.ncbi.nlm.nih.gov/pubmed/37026006 http://dx.doi.org/10.3389/fimmu.2023.1148798 |
Ejemplares similares
-
Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma
por: Brossel, Hélène, et al.
Publicado: (2021) -
HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells
por: Hoyos, Clotilde, et al.
Publicado: (2022) -
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma
por: Staumont, Bernard, et al.
Publicado: (2020) -
Eosinophils and Lung Cancer: From Bench to Bedside
por: Sibille, Anne, et al.
Publicado: (2022) -
Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)